Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors-Reference-Cited by-同舟云学术

Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors

Published:2018-12 Issue: Volume:38 Page:257-264
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Genga Kelly Roveran^ORCID,Lo Cody,Cirstea Mihai S.,Leitao Filho Fernando Sergio,Walley Keith R.,Russell James A.,Linder Adam,Francis Gordon A.,Boyd John H.

Funder

Canadian Institutes of Health Research – CIHR

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference42 articles.

1. Deaths: Final Data for 2016;Xu;Natl Vital Stat Rep,2018

3. Surviving Sepsis Campaign: Association between performance metrics and outcomes in a 7.5-year study;Levy;Crit Care Med,2015

4. Frequency, cost, and risk factors of readmissions among severe sepsis survivors;Goodwin;Crit Care Med,2015

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition;European Journal of Clinical Investigation;2024-06-26

2. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08

3. A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022;Frontiers in Endocrinology;2023-11-29

4. Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis;Critical Care Explorations;2023-11

5. Elevated circulating PCSK9 level is associated with 28-day mortality in patients with sepsis: a prospective cohort study;BMC Emergency Medicine;2023-10-31